{
  "context": {
    "rules": [
      "Rule1: Provided that drug X passes safety, it becomes approved for market.",
      "Rule2: In the event that drug X undergoes committee review, either it passes efficacy or it passes safety.",
      "Rule3: Either drug X undergoes committee review or it undergoes FDA evaluation.",
      "Rule4: Either drug X receives emergency approval, or if it undergoes regulatory process, then whenever it undergoes FDA evaluation, either it passes efficacy or it passes safety.",
      "Rule5: Should drug X be safe, then it is approved.",
      "Rule6: Given that drug X is effective, it becomes available to patients.",
      "Rule7: In cases where drug X is approved for market, it is available to patients.",
      "Rule8: If phase 3 trial is completed, then either drug X is effective or it is approved for market.",
      "Rule9: Whenever drug X meets endpoints, it shows benefit.",
      "Rule10: Should drug X show benefit, then it is approved.",
      "Rule11: In the event that drug X passes efficacy, it is effective.",
      "Rule12: If it is not the case that whenever drug X is not available to patients, it is safe, then drug X is rejected.",
      "Rule13: If it is not the case that whenever drug X is not available to patients, it is safe, then it is not the case that drug X is rejected.",
      "Rule14: Should drug X not be available to patients, then it meets endpoints."
    ],
    "facts": [
      "Fact1: Drug X undergoes regulatory process.",
      "Fact2: Phase 3 trial is completed.",
      "Fact3: It is not the case that drug X is approved.",
      "Fact4: It is not the case that drug X receives emergency approval."
    ]
  },
  "question": "Drug X is available to patients."
}